TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07237659: Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA

Sponsor: Neutrolis · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 24 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$774,180

Rescue Site Savings

+$516,120

Unlock Full NCT07237659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07237659 Rescue Dossier →